Pharsight

Eagle Pharms patents expiration

1. Belrapzo patents expiration

BELRAPZO's oppositions filed in EPO
BELRAPZO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions
Jan, 2026

(1 year, 6 months from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11844783 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11872214 EAGLE PHARMS Formulations of Bendamustine
Jan, 2031

(6 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) Dec 07, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 May, 2018

Treatment: For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with chronic lymphocytic leukemia

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of BELRAPZO before it's drug patent expiration?
More Information on Dosage

BELRAPZO family patents

Family Patents

2. Bendeka patents expiration

BENDEKA's oppositions filed in EPO
BENDEKA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions
Jan, 2026

(1 year, 6 months from now)

US8791270

(Pediatric)

EAGLE PHARMS Bendamustine pharmaceutical compositions
Jul, 2026

(2 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11844783 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11872214 EAGLE PHARMS Formulations of Bendamustine
Jan, 2031

(6 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(7 years from now)

US10052385 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9144568 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9579384 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(8 years from now)

US9597399 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9572887 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9034908 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9000021 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(8 years from now)

US9597397 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9597398 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-179) Dec 07, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 December, 2015

Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of pa...

Dosage: SOLUTION;IV (INFUSION)

How can I launch a generic of BENDEKA before it's drug patent expiration?
More Information on Dosage

BENDEKA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Pemfexy patents expiration

PEMFEXY's oppositions filed in EPO
PEMFEXY IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9604990 EAGLE PHARMS Crystalline forms of pemetrexed diacid and manufacturing processes therefor
Oct, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7772209 EAGLE PHARMS Antifolate combination therapies
May, 2022

(2 years ago)

US11793813 EAGLE PHARMS Pemetrexed formulations
Feb, 2036

(11 years from now)

Drugs and Companies using PEMETREXED ingredient

Market Authorisation Date: 08 February, 2020

Treatment: Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with non-squamous non-small cell lung cancer

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PEMFEXY family patents

Family Patents

4. Ryanodex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884044 EAGLE PHARMS Treatment using dantrolene
Jun, 2022

(2 years ago)

US8604072 EAGLE PHARMS Treatment using dantrolene
Jul, 2022

(1 year, 10 months ago)

US8110225 EAGLE PHARMS Treatment using dantrolene
Dec, 2022

(1 year, 5 months ago)

US8685460 EAGLE PHARMS Treatment using dantrolene
Feb, 2023

(1 year, 3 months ago)

US7758890 EAGLE PHARMS Treatment using dantrolene
Jun, 2025

(1 year, 14 days from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 22, 2021
Orphan Drug Exclusivity(ODE-69) Jul 22, 2021

Drugs and Companies using DANTROLENE SODIUM ingredient

Market Authorisation Date: 22 July, 2014

Treatment: For use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.

Dosage: FOR SUSPENSION;INTRAVENOUS

More Information on Dosage

RYANODEX family patents

Family Patents